Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Background/Aims An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-...

Full description

Bibliographic Details
Main Authors: Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E. Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht
Format: Article
Language:English
Published: Korean Association for the Study of the Liver 2019-03-01
Series:Clinical and Molecular Hepatology
Subjects:
Hepatitis C, Chronic
Biomarkers
Liver cirrhosis
Antiviral agents
Extracellular matrix proteins
Online Access:http://e-cmh.org/upload/pdf/cmh-2018-0029.pdf

Internet

http://e-cmh.org/upload/pdf/cmh-2018-0029.pdf

Similar Items